NSD-726 has been selected as the first preclinical development candidate from one of NeuroSearch’s ion channel drug discovery programmes. The compound has demonstrated a promising effect in preclinical models of certain autoimmune diseases. NSD-726 is under preparation for clinical development with a view to developing the compound to treat a specific autoimmune disorder.
GSK holds an option for NSD-726 under the partnership agreement with NeuroSearch.
